2.25 USD
+0.3 (+15.38%)
2.14 USD
-0.11 (-4.89%)
We assign a fundamental rating of 3 out of 10 to CELZ. CELZ was compared to 525 industry peers in the Biotechnology industry. While CELZ has a great health rating, there are worries on its profitability. CELZ is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- CELZ had negative earnings in the past year.
- CELZ had a negative operating cash flow in the past year.
- CELZ had negative earnings in 4 of the past 5 years.
- CELZ had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of CELZ (-101.85%) is worse than 75.43% of its industry peers.
- CELZ has a Return On Equity (-106.61%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.85% | ||
| ROE | -106.61% | ||
| ROIC | N/A |
ROA(3y)-61.52%
ROA(5y)-1011.99%
ROE(3y)-67.22%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 60.00%, CELZ is in the better half of the industry, outperforming 78.29% of the companies in the same industry.
- In the last couple of years the Gross Margin of CELZ has declined.
- The Profit Margin and Operating Margin are not available for CELZ so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 60% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.52%
GM growth 5Y-3.2%
2. Health
2.1 Basic Checks
- CELZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CELZ has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for CELZ has been increased compared to 5 years ago.
- There is no outstanding debt for CELZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -5.48, we must say that CELZ is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -5.48, CELZ is doing worse than 62.48% of the companies in the same industry.
- There is no outstanding debt for CELZ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.48 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- A Current Ratio of 20.70 indicates that CELZ has no problem at all paying its short term obligations.
- CELZ has a Current ratio of 20.70. This is amongst the best in the industry. CELZ outperforms 96.38% of its industry peers.
- CELZ has a Quick Ratio of 20.70. This indicates that CELZ is financially healthy and has no problem in meeting its short term obligations.
- CELZ has a Quick ratio of 20.70. This is amongst the best in the industry. CELZ outperforms 96.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 20.7 | ||
| Quick Ratio | 20.7 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 23.02% over the past year.
- Looking at the last year, CELZ shows a very negative growth in Revenue. The Revenue has decreased by -45.45% in the last year.
- Measured over the past years, CELZ shows a very negative growth in Revenue. The Revenue has been decreasing by -42.17% on average per year.
EPS 1Y (TTM)23.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)-45.45%
Revenue growth 3Y-50.37%
Revenue growth 5Y-42.17%
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, CELZ will show a very strong growth in Earnings Per Share. The EPS will grow by 27.08% on average per year.
- The Revenue is expected to grow by 535.57% on average over the next years. This is a very strong growth
EPS Next Y43.91%
EPS Next 2Y27.09%
EPS Next 3Y17.66%
EPS Next 5Y27.08%
Revenue Next Year-62.5%
Revenue Next 2Y-41.42%
Revenue Next 3Y1517.11%
Revenue Next 5Y535.57%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CELZ. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELZ. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CELZ's earnings are expected to grow with 17.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.09%
EPS Next 3Y17.66%
5. Dividend
5.1 Amount
- CELZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CREATIVE MEDICAL TECHNOLOGY / CELZ FAQ
What is the ChartMill fundamental rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CELZ.
Can you provide the valuation status for CREATIVE MEDICAL TECHNOLOGY?
ChartMill assigns a valuation rating of 0 / 10 to CREATIVE MEDICAL TECHNOLOGY (CELZ). This can be considered as Overvalued.
How profitable is CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
CREATIVE MEDICAL TECHNOLOGY (CELZ) has a profitability rating of 1 / 10.
Can you provide the financial health for CELZ stock?
The financial health rating of CREATIVE MEDICAL TECHNOLOGY (CELZ) is 7 / 10.
What is the expected EPS growth for CREATIVE MEDICAL TECHNOLOGY (CELZ) stock?
The Earnings per Share (EPS) of CREATIVE MEDICAL TECHNOLOGY (CELZ) is expected to grow by 43.91% in the next year.